Drugmakers carve out immuno-oncology turf

Share this article:
Merck adds heat to HCV competition
Merck adds heat to HCV competition

A clinicaltrials.gov posting noted by ISI Group analyst Mark Schoenebaum has added a new layer of tension to the PD-1 immuno-oncology space.

The goal is to assess the impact of combining Merck's PD-1 antibody MK-3475 with Celgene's Revlimid and dexamethasone could have in multiple myeloma patients who have failed on at least two other treatments.

The roster of companies with late-stage pipeline PD-1s is growing, including Merck, AstraZeneca, Bristol-Myers Squibb and Roche, among others, presenting a potential to knock Revlimid off its game. It is through this optic that Schoenebaum sees this clinical trial as more than a chance to develop a medical treatment: it is also what could be described as a territory-marking strategy.

The deal, according to Schoenebaum's Wednesday analysis, “appears to be a win-win...MRK is exploring MK-3475 in a new indication and market opportunity, and CELG in the face of potential PD1 antibody competition is attempting to insure that Revlimid remains the focus and backbone of myeloma care.”

Oncology has been part of a “renewed” focus of several companies, such as Merck and AstraZeneca, an innovative move that's been accompanied by major layoffs and reorganizations that have cheered investors that robust financial performance will eventually arrive—if they can continue to slog through inevitable pipeline disappointments and profit-bleeding patent losses.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.